1887
Rapid communication Open Access
Like 0

Abstract

The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reassortment such that H156 viruses acquired neuraminidase from clade 3C.2a1b.1a. Vaccine provided substantial protection with A(H3N2) VE of 54% (95% CI: 38 to 66) overall. VE was similar against H156 and vaccine-like S156 viruses, but with potential variation based on diversity at position 135.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.5.2300043
2023-02-02
2024-10-13
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.5.2300043
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/5/eurosurv-28-5-3.html?itemId=/content/10.2807/1560-7917.ES.2023.28.5.2300043&mimeType=html&fmt=ahah

References

  1. Kim S, Chuang ESY, Sabaiduc S, Olsha R, Kaweski SE, Zelyas N, et al. Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada. Euro Surveill. 2022;27(38):2200720.  https://doi.org/10.2807/1560-7917.ES.2022.27.38.2200720  PMID: 36148674 
  2. Buckrell S, Ben Moussa M, Bui T, Rahal A, Schmidt K, Lee L, et al. National influenza annual report, Canada, 2021-2022: A brief, late influenza epidemic. Can Commun Dis Rep. 2022;48(10):473-83.  https://doi.org/10.14745/ccdr.v48i10a07 
  3. Public Health Agency of Canada (PHAC). FluWatch report: January 8 to January 14, 2023 (week 2). Ottawa: PHAC; 2023. [Accessed: 31 Jan 2023). Available from: https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-reports-2022-2023-season.html
  4. Ben Moussa M, Buckrell S, Rahal A, Schmidt K, Lee L, Bastien N, et al. National influenza mid-season report, 2022-2023: A rapid and early epidemic onset. Can Commun Dis Rep. 2023;49(1):10-4.  https://doi.org/10.14745/ccdr.v49i01a03 
  5. European Centre for Disease Prevention and Control (ECDC). Flu New Europe: Joint ECDC-WHO/Europe weekly influenza update. Week 02/2023 (9 January – 15 January 2023). [Accessed: 31 Jan 2023]. Stockholm: ECDC; 2022. Available from: http://flunewseurope.org
  6. Centers for Disease Control and Prevention (CDC). FluView: Past weekly surveillance reports. 2022-2023, January 14, 2023—Week 2. Atlanta: CDC; 2022. [Accessed: 31 Jan 2023]. Available from: https://www.cdc.gov/flu/weekly/pastreports.htm
  7. Skowronski DM, Leir S, Sabaiduc S, Chambers C, Zou M, Rose C, et al. Influenza vaccine effectiveness by A(H3N2) phylogenetic subcluster and prior vaccination history: 2016-2017 and 2017-2018 epidemics in Canada. J Infect Dis. 2022;225(8):1387-98.  https://doi.org/10.1093/infdis/jiaa138  PMID: 32215564 
  8. Canadian Sentinel Practitioner Surveillance Network. Canadian Sentinel Practitioner Surveillance Network (SPSN) influenza vaccine effectiveness estimates % (95% CI), 2004-05 to 2021-22 seasons. [Accessed: 16 Jan 2023]. Available from: http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Publications/Epid/Influenza%20and%20Respiratory/SPSN_VE_By_Year_Table.pdf
  9. National Advisory Committee on Immunization. Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2022-2023. Ottawa (ON): Public Health Agency of Canada; 2022. [Accessed: 22 Jan 2023]. Available from: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2022-2023.html
  10. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. Geneva: WHO; 2022. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-2023-northern-hemisphere-influenza-season
  11. Francis Crick Institute. Worldwide influenza centre. Annual and interim reports. February 2022 and September 2022 interim reports. London: Francis Crick Institute. [Accessed: 16 Jan 2023]. Available from: https://www.crick.ac.uk/research/platforms-and-facilities/worldwide-influenza-centre/annual-and-interim-reports
  12. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterization, summary Europe, November 2022. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/influenza-virus-characterization-summary-europe-november-2022
  13. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976-9.  https://doi.org/10.1126/science.1244730  PMID: 24264991 
  14. Lee J, Neher R, Bedford T. Real-time tracking of influenza A/H3N2 evolution. Nextstrain. [Accessed: 30 Jan 2023]. Available from: https://nextstrain.org/flu/seasonal/h3n2/ha/2y
  15. Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol. 2009;83(19):10309-13.  https://doi.org/10.1128/JVI.01109-09  PMID: 19605485 
  16. Hickman R, Nguyen J, Lee TD, Tyson JR, Azana R, Tsang F, et al. Rapid, high-throughput, cost effective whole genome sequencing of SARS-CoV-2 using a condensed one hour library preparation of the Illumina DNA Prep kit. medRxiv. 2022.02.07.22269672. Pre-print. [Accessed: 26 Jan 2023]  https://doi.org/10.1101/2022.02.07.22269672 .  https://doi.org/10.1101/2022.02.07.22269672 
  17. Illumina. Sequencing the rapidly evolving influenza A virus on the MiSeq system. San Diego: Illumina; 2017. Available from: https://www.illumina.com/content/dam/illumina-marketing/documents/products/appnotes/miseq-nextera-xt-influenza-application-note-770-2015-053.pdf
  18. Kuchinski K. FluViewer [Source code]. 2022 Mar 17 [Accessed: 26 Jan 2023]. GitHub. Available from: https://github.com/KevinKuchinski/FluViewer
  19. Eisler D, Fornika D, Tindale LC, Chan T, Sabaiduc S, Hickman R, et al. Influenza Classification Suite: An automated Galaxy workflow for rapid influenza sequence analysis. Influenza Other Respir Viruses. 2020;14(3):358-62.  https://doi.org/10.1111/irv.12722  PMID: 32064792 
  20. Ndifon W, Wingreen NS, Levin SA. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci USA. 2009;106(21):8701-6.  https://doi.org/10.1073/pnas.0903427106  PMID: 19439657 
  21. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 2017;22(13):30494.  https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494  PMID: 28382917 
  22. Skowronski DM, Sabaiduc S, Leir S, Rose C, Zou M, Murti M, et al. Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV). Euro Surveill. 2019;24(46):1900585.  https://doi.org/10.2807/1560-7917.ES.2019.24.46.1900585  PMID: 31771709 
  23. Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27-38.  https://doi.org/10.1093/biomet/80.1.27 
  24. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409-19.  https://doi.org/10.1002/sim.1047  PMID: 12210625 
  25. Doll MK, Pettigrew SM, Ma J, Verma A. Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors. Clin Infect Dis. 2022;75(1):e564-71.  https://doi.org/10.1093/cid/ciac234  PMID: 35325923 
  26. Kissling E, Pozo F, Martínez-Baz I, Buda S, Vilcu A-M, Domegan L, et al. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study. Influenza Other Respir Viruses. 2023;17(1):e13069.  https://doi.org/10.1111/irv.13069  PMID: 36702797 
  27. Price AM, Flannery B, Talbot HK, Grijalva CG, Wernli KJ, Phillips CH, et al. Influenza vaccine effectiveness against influenza A(H3N2)-related illness in the United States during the 2021-2022 influenza season. Clin Infect Dis. 2022;ciac941.  https://doi.org/10.1093/cid/ciac941  PMID: 36504336 
  28. Kissling E, Pozo F, Buda S, Vilcu A-M, Gherasim A, Brytting M, et al. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort. Euro Surveill. 2019;24(48):1900604.  https://doi.org/10.2807/1560-7917.ES.2019.24.48.1900604  PMID: 31796152 
  29. Francis ME, King ML, Kelvin AA. Back to the future for influenza preimmunity-looking back at influenza virus history to infer the outcome of future infections. Viruses. 2019;11(2):E122.  https://doi.org/10.3390/v11020122  PMID: 30704019 
  30. Griggs EP, Flannery B, Foppa IM, Gaglani M, Murthy K, Jackson ML, et al. Role of age in the spread of influenza, 2011-2019: Data from the US influenza vaccine effectiveness network. Am J Epidemiol. 2022;191(3):465-71.  https://doi.org/10.1093/aje/kwab205  PMID: 34274963 
  31. Schanzer D, Vachon J, Pelletier L. Age-specific differences in influenza A epidemic curves: do children drive the spread of influenza epidemics? Am J Epidemiol. 2011;174(1):109-17.  https://doi.org/10.1093/aje/kwr037  PMID: 21602300 
  32. Potter BI, Kondor R, Hadfield J, Huddleston J, Barnes J, Rowe T, et al. Evolution and rapid spread of a reassortant A(H3N2) virus that predominated the 2017-2018 influenza season. Virus Evol. 2019;5(2):vez046.  https://doi.org/10.1093/ve/vez046  PMID: 33282337 
/content/10.2807/1560-7917.ES.2023.28.5.2300043
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error